Business Context and Reporting Period
Company: Altimmune, Inc.
Filing Type: Form 8-K (Current Report)
Date: December 20, 2022
Subject: Announcement of clinical trial results for pemvidutide (ALT-801) in subjects with non-alcoholic fatty liver disease (NAFLD).
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
The Company announced results from a 24-week (12-week extension) trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist. Key outcomes include:
- Primary Endpoint: Met in all treatment groups. Mean relative reductions in liver fat content were 75.2% (1.8 mg dose) and 76.4% (2.4 mg dose).
- Response Rates: At the 2.4 mg dose, 100% of subjects achieved a 30% reduction in liver fat, and 45.5% achieved normalization (liver fat fraction ≤5%).
- Secondary Endpoints: Statistically significant declines in serum ALT levels were observed. In a subset, 100% of subjects at the 2.4 mg dose achieved an 80 ms decrease in cT1 (a marker for liver inflammation).
- Weight Loss: Mean weight loss was 7.2% (placebo-adjusted 6.0%) in subjects without diabetes and 6.2% (placebo-adjusted 4.8%) in all subjects at the 1.8 mg dose.
- Safety: Pemvidutide was generally well tolerated. Three serious or severe adverse events were reported, all unrelated to the study drug. Gastrointestinal events were the most common and predominantly mild.
Guidance, Outlook, and Risks
Management Commentary: The Company highlighted that the trial was conducted without adjunctive diet and exercise interventions and maintained double-blinding. Glycemic control was maintained with trends toward improvement in fasting glucose and HbA1c. Systolic blood pressure reductions were observed, while heart rate increases were minimal (0 to 4 beats per minute).
Risks and Contingencies: The filing notes that the information provided shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. The Company undertakes no obligation to update, supplement, or amend the materials attached to this report.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and slide presentation (Exhibit 99.2) for detailed statistical analysis.
- Confirm the specific dosing regimens and patient demographics for the 24-week extension period.
- Review the Company's subsequent filings (e.g., 10-K or 10-Q) for financial impact and cash runway, as this 8-K contains no financial data.
- Monitor for updates on the regulatory pathway and potential Phase 2/3 trial designs based on these results.